

Patient Name: DOE, JAMES

Patient Rec. #:

Date of Birth: 01/01/1958 Age: 64

Sex: Male

Date Collected: 12/29/22

Date Received: 12/29/22

Date Reported: 12/29/22

Specimen Number: \$22-000468

Alliance ID:

Ordering Client: THE BEST DOCTOR

Ordering Physician:


Client Address: 7200 W Camino Real, Suite 330


Boca Raton, FL 33433


Telephone: (561) 453-1234 Fax:(561) 453-1238

CC Physician:

## GI PATHOLOGY REPORT







A. Chronic active gastritis, H&E

A. H. pylori stain (40X)

A. STOMACH, ANTRUM BIOPSY:

**DIAGNOSIS:** 

**CHRONIC ACTIVE GASTRITIS.** 

H. PYLORI IMMUNOHISTOCHEMISTRY STAIN IS POSITIVE.

NOTE: No intestinal metaplasia identified. Adequate controls were examined.

**B. SMALL INTESTINE, SECOND PORTION OF DUODENUM BIOPSY:** 

**DIAGNOSIS:** 

DUODENAL MUCOSA WITH MODERATE VILLOUS BLUNTING AND INCREASED INTRAEPITHELIAL LYMPHOCYTES.

NOTE: The findings suggest celiac disease in the appropriate clinical setting. Other associated conditions include medication injury (especially olmesartan and related angiotensin II receptor blockers), infections, and immunemediated disorders. Correlation with celiac disease-associated serological and/or genetic studies is suggested.

## **GROSS DESCRIPTION**

A. Received in formalin with the patient's name and a second identifier and labeled as "ANTRUM" is one minute piece of tan soft tissue that measures 0.3 cm in greatest dimension. It is entirely submitted in one (1) cassette.

B. Received in formalin with the patient's name and a second identifier and labeled as "SECOND PORTION OF DUODENUM" are two pieces of tan soft tissue that measure 0.3 and 0.4 cm each in greatest dimension. Entirely submitted in one (1) cassette.

## **CLINICAL HISTORY**

A. Epigastric and abdominal pain

B. R/o celiac disease.

Electronically Signed by: Mercedes Ficarra, MD. Board Certified in Pathology/Cytopathology

Date: 12/29/2022 Time: 14:27:00

## **SOURCE**

A. ANTRUM

B. SECOND PORTION OF DUODENUM

The tests utilizing analyte-specific reagents (ASR) were developed and their performance characteristics determined by Alliance Laboratories as required by CLIA '88 regulations. They have not been cleared or approved for specific uses by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. Mercedes Ficarra, MD, Laboratory Medical Director Adminor Laboratories '7200 W Camino Real Suite 330, Boca Raton, Ft. 33433 'Phone Number: (561)453-1234 Fax Number: (561)453-1238

\*\*\*Page 1 of 1\*\*

\*\*\*Page 2.000468\*\*

\*\*\*Page 3.000468\*\*

\*\*\*Page